Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3.

Farrelly LA, Thompson RE, Zhao S, Lepack AE, Lyu Y, Bhanu NV, Zhang B, Loh YE, Ramakrishnan A, Vadodaria KC, Heard KJ, Erikson G, Nakadai T, Bastle RM, Lukasak BJ, Zebroski H 3rd, Alenina N, Bader M, Berton O, Roeder RG, Molina H, Gage FH, Shen L, Garcia BA, Li H, Muir TW, Maze I.

Nature. 2019 Mar;567(7749):535-539. doi: 10.1038/s41586-019-1024-7. Epub 2019 Mar 13.

PMID:
30867594
2.

Cell-type-specific role for nucleus accumbens neuroligin-2 in depression and stress susceptibility.

Heshmati M, Aleyasin H, Menard C, Christoffel DJ, Flanigan ME, Pfau ML, Hodes GE, Lepack AE, Bicks LK, Takahashi A, Chandra R, Turecki G, Lobo MK, Maze I, Golden SA, Russo SJ.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1111-1116. doi: 10.1073/pnas.1719014115. Epub 2018 Jan 16.

3.

Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, Duman RS.

Biol Psychiatry. 2018 Jan 1;83(1):29-37. doi: 10.1016/j.biopsych.2017.06.017. Epub 2017 Jun 23.

4.

Aberrant H3.3 dynamics in NAc promote vulnerability to depressive-like behavior.

Lepack AE, Bagot RC, Peña CJ, Loh YE, Farrelly LA, Lu Y, Powell SK, Lorsch ZS, Issler O, Cates HM, Tamminga CA, Molina H, Shen L, Nestler EJ, Allis CD, Maze I.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12562-12567. Epub 2016 Oct 18.

5.

Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

Lepack AE, Bang E, Lee B, Dwyer JM, Duman RS.

Neuropharmacology. 2016 Dec;111:242-252. doi: 10.1016/j.neuropharm.2016.09.011. Epub 2016 Sep 12.

6.

Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.

Navarria A, Wohleb ES, Voleti B, Ota KT, Dutheil S, Lepack AE, Dwyer JM, Fuchikami M, Becker A, Drago F, Duman RS.

Neurobiol Dis. 2015 Oct;82:254-261. doi: 10.1016/j.nbd.2015.06.012. Epub 2015 Jun 21.

7.

Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.

Dwyer JM, Maldonado-Avilés JG, Lepack AE, DiLeone RJ, Duman RS.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6188-93. doi: 10.1073/pnas.1505289112. Epub 2015 Apr 27.

8.

BDNF release is required for the behavioral actions of ketamine.

Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu033. doi: 10.1093/ijnp/pyu033.

9.

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.

Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK.

Neuropsychopharmacology. 2013 Oct;38(11):2268-77. doi: 10.1038/npp.2013.128. Epub 2013 May 17.

10.

mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure.

Dwyer JM, Lepack AE, Duman RS.

J Mol Psychiatry. 2013 Sep 17;1(1):15. doi: 10.1186/2049-9256-1-15. eCollection 2013.

11.

mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.

Dwyer JM, Lepack AE, Duman RS.

Int J Neuropsychopharmacol. 2012 May;15(4):429-34. doi: 10.1017/S1461145711001702. Epub 2011 Nov 24.

Supplemental Content

Loading ...
Support Center